First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan

Objective Ascites in patients with decompensated cirrhosis can lead to abdominal distention and decrease quality of life. Tolvaptan, a vasopressin V2 receptor antagonist, is an effective agent in the treatment of ascites, whereas some patients are refractory to tolvaptan. The efficacy of transjugula...

Full description

Bibliographic Details
Main Authors: Tatehiro Kagawa, Kota Tsuruya, Jun Koizumi, Yuka Sekiguchi, Shun Ono, Tatsuya Sekiguchi, Takuya Hara, Yusuke Mishima, Yoshitaka Arase, Shunji Hirose, Koichi Shiraishi
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/10/1/e001120.full

Internet

https://bmjopengastro.bmj.com/content/10/1/e001120.full

Similar Items